Foundation Medicine
Molecular insight company, connects physicians & patients to the latest cancer treatment
Based in MA
🤖
AI Overview
With $1.7M in lobbying spend across 22 quarterly filings, Foundation Medicine is a significant lobbying presence. They deploy 12 individual lobbyists
$1.7M
Total Lobbying Spend
22
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2020 | $190K |
| 2021 | $400K |
| 2022 | $400K |
| 2023 | $320K |
| 2024 | $240K |
| 2025 | $160K |
Lobbying Firms
TARPLIN, DOWNS & YOUNG, LLC
What They Lobby For
- Companion diagnostics, genomics testing, cancer therapies, FDA user fee reauthorization
- companion diagnostics H.R. 6800 - The Heroes Act
- companion diagnostics
- companion diagnostics H.R. 6800 - The Heroes Act H.R. 133 - Consolidated Appropriations Act, 2021 testing
- companion diagnostics H.R. 133 - Consolidated Appropriations Act, 2021
- companion diagnostics payment issues H.R. 1319, American Rescue Pan of 2021
- companion diagnostics testing innovation surprise billing implementation H.R. 1319, American Rescue Plan of 2021
- companion diagnostics testing innovation surprise billing implementation H.R. 1319, American Rescue Plan of 2021 implementation
- companion diagnostics payment issues H.R. 1319, American Rescue Plan of 2021 implementation
- companion diagnostics testing innovation surprise billing implementation H.R. 1319, American Rescue Plan of 2021 implementation H.R. 3, The Lower Drug Costs Now Act
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.